PMID- 18432635
OWN - NLM
STAT- MEDLINE
DCOM- 20080703
LR  - 20221230
IS  - 1934-368X (Electronic)
IS  - 1934-3671 (Linking)
VI  - Chapter 20
DP  - 2008 Feb
TI  - Carcinoembryonic antigen transgenic mouse models for immunotherapy and 
      development of cancer vaccines.
PG  - 20.8.1-20.8.12
LID - 10.1002/0471142735.im2008s80 [doi]
AB  - The goal of cancer therapy remains as the long-term eradication of tumor cells 
      without adverse effects on normal tissue. Conventional approaches utilizing 
      chemotherapy and radiotherapy are limited by both their toxicity and lack of 
      specificity. In recent years, investigators have carried out several studies 
      designed to evaluate whether human tumor-associated antigens (TAAs) can be 
      exploited as targets for immunotherapy, specifically for human cancer vaccine 
      development. A major limitation in immunotherapy studies of human cancer is the 
      general lack of appropriate preclinical models. Clinical studies can be difficult 
      to implement, particularly when a clear understanding of the potential efficacy, 
      limitation, and safety of an immunotherapeutic strategy is not available from 
      relevant animal investigations. However, mice carrying a transgene for a human 
      tumor self-antigen may provide a more acceptable experimental model in which 
      knowledge about immunotherapeutic strategies aiming at the TAA of interest can be 
      enhanced prior to initiating clinical trials. Since the different strategies in 
      experimental immunotherapy of cancer have been directed to activate different 
      immune system components, a variety of transgenic mouse models have been 
      generated expressing either TAA, human leukocyte antigen (HLA), oncogene, or 
      immune effector cell molecules. These models may serve as an excellent platform 
      for the identification of novel targets for immunotherapy as well as to evaluate 
      the efficacy of targeted therapies and will lead to the development of clinical 
      trials for cancer patients. In this unit, a brief overview of the generation and 
      study of different vaccine approaches in carcinoembryonic antigen (CEA) 
      transgenic mouse models and the experimental findings in mouse models that 
      spontaneously develop gastrointestinal tumors and express the CEA transgene is 
      provided.
CI  - (c) 2008 by John Wiley & Sons, Inc.
FAU - Bhattacharya-Chatterjee, Malaya
AU  - Bhattacharya-Chatterjee M
AD  - University of Cincinnati Medical Center, Cincinnati, Ohio.
FAU - Saha, Asim
AU  - Saha A
AD  - University of Cincinnati Medical Center, Cincinnati, Ohio.
FAU - Foon, Kenneth A
AU  - Foon KA
AD  - University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
FAU - Chatterjee, Sunil K
AU  - Chatterjee SK
AD  - University of Cincinnati Medical Center, Cincinnati, Ohio.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Protoc Immunol
JT  - Current protocols in immunology
JID - 9101651
RN  - 0 (Cancer Vaccines)
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Vaccines, DNA)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/genetics/immunology/therapeutic use
MH  - *Carcinoembryonic Antigen/genetics/immunology
MH  - Gastrointestinal Neoplasms/genetics/immunology/pathology/therapy
MH  - Humans
MH  - *Immunotherapy/methods
MH  - Mice
MH  - Mice, Transgenic
MH  - *Models, Animal
MH  - Neoplasms, Experimental/genetics/*immunology/pathology/therapy
MH  - T-Lymphocytes, Cytotoxic/immunology/pathology
MH  - Vaccines, DNA/therapeutic use
MH  - Vaccines, Subunit/genetics/immunology/therapeutic use
RF  - 91
EDAT- 2008/04/25 09:00
MHDA- 2008/07/04 09:00
CRDT- 2008/04/25 09:00
PHST- 2008/04/25 09:00 [pubmed]
PHST- 2008/07/04 09:00 [medline]
PHST- 2008/04/25 09:00 [entrez]
AID - 10.1002/0471142735.im2008s80 [doi]
PST - ppublish
SO  - Curr Protoc Immunol. 2008 Feb;Chapter 20:20.8.1-20.8.12. doi: 
      10.1002/0471142735.im2008s80.